AMENDMENTS

Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

- 1.-53. (Canceled)
- 54. (Canceled) A method of treating a subject having cancer, comprising administering to said individual a therapeutically effective amount of a composition comprising N-(4-hydroxyphenyl) retamide, or a derivative thereof, encapsulated in a lipid material, wherein said lipid material comprises dimyristoyl phosphatidylcholine (DMPC) and one or more of soybean oil (SO) and water.
- 55. (Canceled) The method of claim 54, wherein said dimyristoyl phosphatidylcholine and soybean oil comprise a ratio of greater than 80:20.
- 56. (Canceled) The method of claim 54, wherein said composition is comprised in a pharmaceutically acceptable aqueous medium.
- 57. (Canceled) The method of claim 54, wherein said method further comprises administering at least one additional therapeutic agent to said individual.
- 58. (Canceled) The method of claim 57, wherein said agent is comprised in said composition.
- 59. (Canceled) The method of claim 57, wherein said additional therapeutic agent comprises at least one anticancer agent.
- 60. (Canceled) The method of claim 59, wherein the anticancer agent is chemotherapy agent, a radiotherapy agent, an immune therapy agent, a genetic therapy agent, a hormonal therapy agent, a biological agent, an additional retinoid or a retinoid derivative.

- 61. (Withdrawn) A method for increasing growth inhibitory effects of fenretinide on a cell comprising providing to a cell, in combination with fenretinide, one or more agents that increases the level of nitric oxide (NO) in said cell.
- 62. (Withdrawn) The method of claim 61, wherein said cell is a tumor cell.
- 63. (Withdrawn) The method of claim 62, wherein said tumor cell is a breast cancer cell.
- 64. (Withdrawn) The method of claim 63, wherein the breast cancer cell is an estrogen receptor (ER)-positive cell.
- 65. (Withdrawn) The method of claim 63, wherein the breast cancer cell is an estrogen receptor (ER)-negative cell.
- 66. (Withdrawn) The method of claim 61, wherein fenretinide is provided before the one or more agents.
- 67. (Withdrawn) The method of claim 61, wherein fenretinide is provided at the same time as the one or more agents.
- 68. (Withdrawn) The method of claim 61, wherein fenretinide is provided after the one or more agents.
- 69. (Withdrawn) The method of claim 61, wherein fenretinide is provided more than once.
- 70. (Withdrawn) The method of claim 69, wherein fenretinide is provided daily for three months with monthly three-day interruptions.
- 71. (Withdrawn) The method of claim 61, wherein said agent is provided more than once.

- 72. (Withdrawn) The method of claim 61, wherein said agent is a nucleic acid.
- 73. (Withdrawn) The method of claim 72, wherein said nucleic acid is an expression construct encoding iNOS, interferon-γ or herceptin.
- 74. (Withdrawn) The method of claim 61, wherein said agent is a protein.
- 75. (Withdrawn) The method of claim 74, wherein said protein is iNOS, interferon-γ or herceptin.
- 76. (Withdrawn) The method of claim 61, wherein said agent is a chemopharmaceutical.
- 77. (Withdrawn) The method of claim 76, wherein said agent is cyclosporin A.
- 78. (Withdrawn) The method of claim 62, wherein said cell tumor cell is a patient.
- 79. (Withdrawn) The method of claim 78, wherein said cell tumor cell is part of a tumor mass in said patient.
- 80. (Withdrawn) The method claim 78, wherein providing comprises direct administration to said tumor cell.
- 81. (Withdrawn) The method of claim 61, further comprising providing to said cell an additional anti-cancer therapy.
- 82. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is radiation.
- 83. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is a distinct chemotherapy.

- 84. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is a distinct gene therapy.
- 85. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is immunotherapy.
- 86. (Withdrawn) The method of claim 81, wherein said additional anti-cancer therapy is hormonal therapy.
- 87. (Withdrawn) The method of claim 61, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration of 0.1 µm.
- 88. (Withdrawn) The method of claim 61, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration of 0.5 μm.
- 89. (Withdrawn) The method of claim 61, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration of 1.0 μm.
- 90. (Withdrawn) The method of claim 61, wherein said cell is killed.
- 91. (Withdrawn) A method for treating cancer in a subject comprising providing to said subject, in combination, fenretinide and one or more agents that increases the level of nitric oxide (NO) in cancer cells in said subject.
- 92. (Withdrawn) The method of claim 91, wherein said cancer is a breast cancer.
- 93. (Withdrawn) The method of claim 92, wherein cells of said breast cancer are estrogen receptor (ER)-positive.

- 94. (Withdrawn) The method of claim 92, wherein cells of said breast cancer are estrogen receptor (ER)-negative.
- 95. (Withdrawn) The method of claim 91, wherein fenretinide is provided before the one or more agents.
- 96. (Withdrawn) The method of claim 91, wherein fenretinide is provided at the same time as the one or more agents.
- 97. (Withdrawn) The method of claim 91, wherein fenretinide is provided after the one or more agents.
- 98. (Withdrawn) The method of claim 91, wherein fenretinide is provided more than once.
- 99. (Withdrawn) The method of claim 98, wherein fenretinide is provided daily for three months with monthly three-day interruptions.
- 100. (Withdrawn) The method of claim 91, wherein said agent is provided more than once.
- 101. (Withdrawn) The method of claim 91, wherein said agent is a nucleic acid.
- 102. (Withdrawn) The method of claim 101, wherein said nucleic acid is an expression construct encoding iNOS, interferon-γ or herceptin.
- 103. (Withdrawn) The method of claim 91, wherein said agent is a protein.
- 104. (Withdrawn) The method of claim 103, wherein said protein is iNOS, interferon-γ or herceptin.
- 105. (Withdrawn) The method of claim 91, wherein said agent is a chemopharmaceutical.

- 106. (Withdrawn) The method of claim 105, wherein said agent is cyclosporin A.
- 107. (Withdrawn) The method claim 91, wherein providing comprises direct administration to said tumor cell.
- 108. (Withdrawn) The method of claim 91, further comprising providing to said cell an additional anti-cancer therapy.
- 109. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is radiation.
- 110. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is a distinct chemotherapy.
- 111. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is a distinct gene therapy.
- 112. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is immunotherapy.
- 113. (Withdrawn) The method of claim 108, wherein said additional anti-cancer therapy is hormonal therapy.
- 114. (Withdrawn) The method of claim 91, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration in cancer cells of $0.1~\mu m$.
- 115. (Withdrawn) The method of claim 91, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration in cancer cells of 0.5 μ m.

- 116. (Withdrawn) The method of claim 91, wherein fenretinide is provided in an amount sufficient to achieve an intracellular concentration in cancer cells of 1.0 μm.
- 117. (Withdrawn) The method of claim 91, wherein fenretinide is provided at 10 mg/day.
- 118. (Withdrawn) The method of claim 91, wherein fenretinide is provided at 100 mg/day.
- 119. (Withdrawn) The method of claim 91, wherein fenretinide is provided at 200 mg.day.
- 120. 129. (Cancelled)
- 130. (Withdrawn) A method for inhibiting metastasis in a subject having cancer comprising providing to said subject, in combination, fenretinide and one or more agents that increases the level of nitric oxide (NO) in cancer cells in said subject.
- 131. (Canceled) The method of claim 54, wherein the composition is administered parenterally to the individual.
- 132. (Canceled) The method of claim 54, wherein the composition is administered orally to the individual.
- 133. (Canceled) The method of claim 54, wherein the lipid material comprises DMPC and SO.
- 134. (Canceled) The method of claim 133, comprising a ratio of 4-HPR, or derivative thereof, to DMPC/SO of from 1:5 to 1:15.
- 135. (Canceled) The method of claim 134, wherein the 4-HPR, or derivative thereof, to DMPC/SO ratio is about 1:5 (w/w).

- 136. (Canceled) The method of claim 134, wherein the 4-HPR, or derivative thereof, to DMPC/SO ratio is about 1:10 (w/w).
- 137. (Canceled) The method of claim 134, wherein the 4-HPR, or derivative thereof, to DMPC/SO ratio is about 1:15 (w/w).
- 138. (Currently amended) A method of treating a subject having cancer, comprising administering to said individual a therapeutically effective amount of a composition comprising N-(4-hydroxyphenyl) retamide, or a derivative thereof, encapsulated in a lipid material, The method of claim 54, wherein the lipid material comprises dimyristoyl phosphatidylcholine (DMPC) and water.
- 139. (Previously presented) The method of claim 138, wherein the composition comprises from 1 to 10% water.
- 140. (Previously presented) The method of claim 139, wherein the composition comprises about 10% water.
- 141. (Currently amended) A method of treating a subject having cancer, comprising administering to said individual a therapeutically effective amount of a composition comprising N-(4-hydroxyphenyl) retamide, or a derivative thereof, encapsulated in a lipid material, The method of claim 54, wherein the lipid material comprises dimyristoyl phosphatidylcholine (DMPC), soybean oil (SO) and water.